Screener
Agios Pharmaceuticals AGIO Business Segments — SG&A
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Agios Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.
The source filing: Agios Pharmaceuticals’s 10-Q, filed July 30, 2026.
- Filed
- Jul 30, 2026, 9:56 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001439222-26-000118
| (In thousands) | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Product revenue, net - U.S. | $40,917 | $12,151 | $59,768 | $20,877 |
| Product revenue, net - Rest of world | 3,828 | 304 | 5,723 | 304 |
| PK activator (PYRUKYND®/AQVESME™) direct expenses - research and development | (25,849) | (29,809) | (49,754) | (51,130) |
| Compensation and related expenses - research and development | (30,352) | (27,594) | (67,141) | (60,584) |
| Total selling, general and administrative expenses | (51,547) | (45,869) | (99,851) | (87,396) |
| Other segment items* | (37,700) | (21,203) | (48,559) | (23,380) |
| Net loss | $(100,703) | $(112,020) | $(199,814) | $(201,309) |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Agios Pharmaceuticals's business segments — SG&A?
- Agios Pharmaceuticals (AGIO) reported business segments — SG&A of $51.55M in Q2 2026.
- How has Agios Pharmaceuticals's business segments — SG&A changed year-over-year?
- Agios Pharmaceuticals's business segments — SG&A increased by 12.4% year-over-year, from $45.87M to $51.55M.
- What is the long-term trend for Agios Pharmaceuticals's business segments — SG&A?
- Over 3 years (2022 to 2025), Agios Pharmaceuticals's business segments — SG&A has grown at a 29.4% compound annual growth rate (CAGR), from -$121.67M to -$263.33M.
- What does business segments — SG&A mean?
- This metric aggregates the selling, general, and administrative expenses associated with the reportable segment, covering overhead, corporate support, and commercialization efforts. It reflects the operational costs required to maintain business functions outside of direct research and development. Investors use this to evaluate the company's operational efficiency and the scalability of its administrative infrastructure.
Ask your AI about Agios Pharmaceuticals's business segments — sg&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude